CPD Login
CPD Login
Australia should prepare now for a potential influx of synthetic opioids into the illicit drug market, an expert has told Australian Pharmacist, as overdoses increase internationally.
A worldwide Vyvanse, expected to last months, has left pharmacists inundated with requests for the popular ADHD medicine.
While the NIPVIP Program has been underway for almost a month, eligibility is still a murky area for many patients and pharmacists alike.
With reports of children as young as 5 attempting suicide and low efficacy, here’s how pharmacists can approach montelukast supply.
The timelines and alternative options for thousands of patients living with pain when oral morphine and oxycodone are discontinued this year.
With the right knowledge, pharmacists can help heal patients’ acute wounds and injuries — and grow a gaping area of practice.
It’s been another big year for pharmacy practice. Before we wrap up 2023, it’s time to put your knowledge to the test.
Preparing for the National Immunisation Program Vaccinations in Pharmacy program, commencing on 1 January 2024.
As we head into festival season, revellers from most states and territories could be placed in a potentially deadly situation.
Glucagon-like peptide 1 (GLP-1) agonists, traditionally used to manage type 2 diabetes, have been increasingly prescribed off-label for weight loss.  There are four GLP-1 agonist medicines approved by the Therapeutic Goods Administration (TGA) for use in Australia for the management...